Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.21.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Organization And Summary Of Significant Accounting Policies [Line Items]        
Cash, cash equivalents, and marketable securities $ 175.4   $ 175.4  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 65.00% 64.00% 19.00% 47.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 0.00% 36.00% 63.00% 32.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | BMS        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 35.00% 0.00% 18.00% 0.00%
Other Assets        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Restricted cash $ 3.7   $ 3.7